TRVI vs VERA
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
TRVI · Trevi Therapeutics$14.33 ▲ 11.87%
VERA · Vera Therapeutics$29.79 ▼ 1.18%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- TRVI +22.8%
- VERA +7.3%
Head to head
| Metric | TRVI | VERA |
|---|---|---|
| Price | $14.33 | $29.79 |
| Change today | ▲ 11.87% | ▼ 1.18% |
| Market cap | $2.04B | $2.15B |
| Return, 3 months | -19.5% | -5.7% |
| Return, year to date | +14.5% | -41.2% |
| Return, 1 year | +30.2% | +23.1% |
| P/E (TTM) | – | – |
| P/B | 6.3 | 6.5 |
| P/E percentile vs own 5y | 10th | 72nd |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | – | – |
| Net profit growth (YoY) | -44.7% | -43.0% |
| Gross margin | – | – |
| Operating margin | – | – |
| Net margin | – | – |
| Return on equity | -19.7% | -91.8% |
| Analyst target vs. price | +102.4% | +152.9% |
| Analyst buy share | 100% | 91% |
| RSI (14) | 57 | 48 |
| 30-day volatility | 58.8% | 56.6% |
| Max drawdown, 1 year | -39.1% | -52.0% |
| Trend read | Leaning bullish | Leaning bearish |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- VERA is the largest of the group by market value.
- TRVI has returned the most over the past year.
- VERA has been the calmest stock over the last 30 days.